Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-12-24Clinical Trial Update: Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk [Phase 2]
Phase 2 trial comparing decitabine to azacitidine in myelodysplastic syndrome patients with low and intermediate-1 risk; results completed w…
-
CLINICAL_TRIALS trial_result · 2020-12-08Clinical Trial Update: Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease [Phase 2]
Phase 2 pharmacokinetics study of intravenous anidulafungin (Ecalta) in patients at high risk for invasive fungal disease has been completed…
-
CLINICAL_TRIALS trial_result · 2020-12-08Clinical Trial Update: Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease [Phase 2]
Phase 2 trial update comparing twice-weekly intravenous micafungin pharmacokinetics to daily dosing in patients at risk for invasive fungal …
-
CLINICAL_TRIALS trial_result · 2020-12-08Clinical Trial Update: Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) [Phase 2]
Phase 2 trial update of clo farabine combinations in relapsed/refractory AML and MDS (and myeloid blast phase CML) with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-27Clinical Trial Update: Combined Haploidentical-Cord Blood Transplantation for Adults and Children [NA]
Clinical trial update on combined haploidentical-cord blood transplantation in adults and children for leukemia and myelodysplastic syndrome…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) [Phase 1, Phase 2]
Phase 1/2 trial evaluating pharmacokinetic guided dose escalation and confirmation using oral decitabine with the oral cytidine deaminase in…
-
CLINICAL_TRIALS trial_result · 2020-10-12Clinical Trial Update: Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial evaluating donor lymphocyte infusion with azacitidine to prevent relapse after stem cell transplantation.
-
FDA approval · 2020-09-22FDA Approved: AZACITIDINE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for Dr. Reddy's azacitidine (AZACITIDINE).
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM [Phase 1, Phase 2]
Phase 1/2 clinical trial update for NiCord (umbilical cord blood-derived ex vivo expanded cells) in hematological malignancies, including AL…
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial evaluating a stem cell transplant using peripheral and cord blood stem cells for severe aplastic anemia and myelodysp…
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant [Phase 3]
Phase 3 clinical trial update for INSPIRE program addressing information/resources for long-term cancer survivors who underwent stem cell tr…
-
CLINICAL_TRIALS trial_result · 2020-07-30Clinical Trial Update: Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) [Phase 3]
Phase III trial comparing treosulfan-based conditioning to reduced-intensity conditioning in acute myeloid leukemia and myelodysplastic synd…
-
FDA label_change · 2020-07-23FDA Approved: JADENU — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental application for JADENU (deferasirox) from Novartis, updating the product labeling.
-
FDA approval · 2020-07-07FDA Approved: INQOVI — Original Application (Taiho Pharmaceutical Co., Ltd.)
FDA approved INQOVI (cedazuridine and decitabine) from Taiho Pharmaceutical Co., Ltd. under an original NDA (NDA 212576) for adults with mye…
-
CLINICAL_TRIALS trial_result · 2020-07-01Clinical Trial Update: Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating deferasirox for very low/low/intermediate-risk transfusion-dependent anemia and myelodysplastic syndrome was termin…
-
FDA approval · 2020-06-08FDA Approved: AZACITIDINE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s generic azacitidine (AZACITIDINE) through an Original Application (ANDA 209337). This adds a g…
-
CLINICAL_TRIALS trial_result · 2020-05-26Clinical Trial Update: Preventing Stem Cell Transplant Complications With a Blood Separator Machine [Phase 1, Phase 2]
Phase 1/2 clinical trial investigating a blood separator machine to prevent complications after stem cell transplant.
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status [Phase 1]
Phase I study of AC220 (trastuz? actually AC220 is quizartinib, a FLT3 inhibitor) in relapsed/refractory AML regardless of FLT3 status; comp…
-
CLINICAL_TRIALS trial_result · 2020-04-21Clinical Trial Update: Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR [NA]
Clinical trial update on donor-derived humoral immunity and hematopoietic stem cell transplantation completed with posted results in 2020.
-
FDA approval · 2020-04-13FDA Approved: DEFERASIROX — Supplemental Application (Xiromed, LLC)
The FDA approved a supplemental application for deferasirox filed by Xiromed, LLC under an ANDA.
-
CLINICAL_TRIALS trial_result · 2020-03-27Clinical Trial Update: A Randomized Trial of rhTPO Versus Placebo for Low/Intermediate-1 Risk MDS With Thrombocytopenia [Phase 2, Phase 3]
A randomized trial compares rhTPO to placebo for thrombocytopenia in patients with Low/Intermediate-1 risk myelodysplastic syndrome (MDS). P…
-
FDA approval · 2020-03-18FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for Vidaza (azacitidine) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2020-03-17Clinical Trial Update: Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating decitabine with the GCLAM regimen in adults with newly diagnosed, relapsed, or refractory acute myeloi…
-
CLINICAL_TRIALS trial_result · 2020-02-26Clinical Trial Update: The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS) [Phase 3]
A Phase 3 trial assessed oral azacitidine plus best supportive care versus placebo and best supportive care in transfusion-dependent, low-ri…
-
CLINICAL_TRIALS trial_result · 2020-02-24Clinical Trial Update: Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
Phase 1/2 trial comparing CIA versus FLAI in acute myeloid leukemia and high-risk myelodysplastic syndrome completed with posted results.